KLRK1 and acute myeloid leukemia: Multiple recent studies demonstrate dysregulation of ILC subsets in AML patients, including a hypo-mature NK cell phenotype, impaired NK cytotoxicity and decreased IFNγ secretion, decreased expression of the NK receptor activating surface marker NKG2D, and hypo-functional type 1 ILCs [43,47,48,49].